Press Releases

Press Releases

or

December 6, 2020
Zanubrutinib was shown to be highly active in patients with relapsed/refractory marginal zone lymphoma in initial results from the Phase 2 MAGNOLIA trial Zanubrutinib demonstrated an overall response rate of nearly 95 percent and a sustained progression-free survival in treatment-naïve chronic
December 1, 2020
CAMBRIDGE, Mass. & BEIJING --(BUSINESS WIRE)--Dec. 1, 2020-- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced the pricing of an underwritten public offering of 1,511,546
December 1, 2020
CAMBRIDGE, Mass. & BEIJING --(BUSINESS WIRE)--Dec. 1, 2020-- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced the commencement of an underwritten public offering of 1,511,546
November 19, 2020
BEIJING & CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 19, 2020-- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that the China National Medical Products Administration (NMPA)
November 5, 2020
CAMBRIDGE, Mass. & BEIJING --(BUSINESS WIRE)--Nov. 5, 2020-- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today reported recent business highlights, anticipated upcoming milestones, and